Short Interest in Delcath Systems, Inc. (NASDAQ:DCTH) Drops By 20.5%

Delcath Systems, Inc. (NASDAQ:DCTH - Get Free Report) was the target of a large drop in short interest in February. As of February 28th, there was short interest totalling 700,600 shares, a drop of 20.5% from the February 13th total of 881,500 shares. Based on an average daily volume of 401,400 shares, the short-interest ratio is presently 1.7 days. Approximately 2.7% of the company's stock are sold short.

Analyst Upgrades and Downgrades

DCTH has been the topic of a number of research analyst reports. Craig Hallum upped their price target on Delcath Systems from $18.00 to $21.00 and gave the company a "buy" rating in a report on Friday, January 17th. HC Wainwright raised their price target on shares of Delcath Systems from $22.00 to $24.00 and gave the company a "buy" rating in a report on Friday, March 7th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $22.75.

Institutional Investors Weigh In On Delcath Systems

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Vivo Capital LLC grew its holdings in Delcath Systems by 71.4% during the fourth quarter. Vivo Capital LLC now owns 1,708,579 shares of the company's stock valued at $20,571,000 after purchasing an additional 711,574 shares during the period. Soleus Capital Management L.P. purchased a new position in shares of Delcath Systems during the 4th quarter valued at about $9,644,000. Gilder Gagnon Howe & Co. LLC bought a new position in shares of Delcath Systems during the 4th quarter valued at approximately $7,371,000. Millennium Management LLC grew its stake in shares of Delcath Systems by 53.4% during the 4th quarter. Millennium Management LLC now owns 314,675 shares of the company's stock valued at $3,789,000 after acquiring an additional 109,568 shares during the period. Finally, Geode Capital Management LLC increased its holdings in Delcath Systems by 14.7% in the 4th quarter. Geode Capital Management LLC now owns 288,951 shares of the company's stock worth $3,481,000 after acquiring an additional 37,056 shares in the last quarter. 61.12% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Delcath Systems Stock Down 2.0 %

Shares of Delcath Systems stock traded down $0.28 during trading hours on Friday, reaching $13.72. 468,762 shares of the stock traded hands, compared to its average volume of 336,725. Delcath Systems has a one year low of $4.26 and a one year high of $16.97. The firm has a market capitalization of $458.29 million, a price-to-earnings ratio of -10.16 and a beta of 0.82. The company has a 50 day moving average price of $14.51 and a 200 day moving average price of $11.88.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last announced its earnings results on Thursday, March 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.01). Delcath Systems had a negative net margin of 150.70% and a negative return on equity of 338.16%. The business had revenue of $15.10 million for the quarter, compared to the consensus estimate of $14.96 million. During the same quarter last year, the firm posted ($0.48) earnings per share. Sell-side analysts anticipate that Delcath Systems will post -0.79 earnings per share for the current year.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.